-+ 0.00%
-+ 0.00%
-+ 0.00%

Johnson & Johnson Announces Data From Its VARIPURE, Omny-IRE Trials Demonstrated 100% Of Participants Had Acute Procedural Success; Mean Ablation Rate Of 17.9 Minutes Observed

Benzinga·10/22/2026 11:47:50
Listen to the news

Johnson & Johnson (NYSE: JNJ) today announced new data from the late-breaking VARIPURE and Omny-IRE studies presented at the Asia Pacific Heart Rhythm Society (APHRS) 2026 Annual Meeting in Busan, South Korea. Both studies were published simultaneously in Europace and Heart Rhythm, respectively.

  • Effectiveness and safety results: enrolled patients had 100% acute procedural success. Study data also shows one primary adverse event (0.4%) that was resolved without sequelae, and zero reported stroke, coronary spasm, acute kidney injury, or death.i
  • Workflow evaluation: Mean ablation duration of 17.9 minutes, and single-catheter mapping and ablation used in 88.9% of cases.